
What the trials actually reported
In SURMOUNT-1, alopecia was reported by roughly 4 to 6 percent of tirzepatide patients versus about 1 percent on placebo. That pattern matches what rapid weight loss does through any method, including bariatric surgery and aggressive dieting.
The mechanism: telogen effluvium
A large energy deficit pushes an unusual share of follicles into their resting phase at once; the shed shows up two to four months later. It looks dramatic and is temporary – follicles are not damaged and the cycle normalizes as weight stabilizes.
What usually helps
Protein at every meal, steady nutrition rather than deeper cutting, and asking your clinician about iron, vitamin D, and thyroid checks if shedding is heavy. Slower titration can soften the trigger by slowing the pace of loss.
Approval status for every brand product is verifiable in Drugs@FDA.
When it is something else
Patchy loss, scalp symptoms, eyebrow or body-hair loss, or shedding that continues long after weight stabilizes do not fit the telogen pattern and deserve a proper evaluation. PinwellRx also offers clinician-guided hair-loss care where appropriate. See the 30-second film answers for this medication.
Why progress slows, and what a clinician looks at
Weight change is rarely linear, and a slowdown is the expected shape rather than a failure of the medication. Physiologically, energy requirements fall as body mass falls, so the same intake that once produced a deficit eventually does not. Appetite signalling also adapts. When someone reports a stall, a clinician generally reviews dose and where you are in the titration schedule, protein intake and resistance training as they relate to lean mass, sleep, alcohol, and other medications that affect weight independently. Some of those are adjustable and some are not. What a clinician will not do is promise that a dose increase resolves it. If lean mass is the concern, protecting muscle during treatment goes into what the evidence does and does not support.
How tirzepatide works on two receptors at once
Tirzepatide is a single molecule that activates two incretin receptors: GIP and GLP-1. Both are receptors your gut already uses. After a meal, the intestine releases incretin hormones that tell the pancreas to release insulin, slow how fast the stomach empties, and signal fullness to the hypothalamus. Tirzepatide binds those same receptors, so the signal is present at a steadier level than it would be from food alone. The GLP-1 arm is the one most people have heard of. The GIP arm is what distinguishes tirzepatide from semaglutide, which acts on GLP-1 only. According to the FDA prescribing information for tirzepatide products, dual agonism is the mechanism of record. What that difference means for any individual is a clinical question, not a settled one, and a licensed clinician decides whether the medication is appropriate for you at all.
What compounded means, and what it does not
A compounded preparation is made by a licensed pharmacy for an individual patient on receipt of a valid prescription. Compounded drugs are not FDA-approved, and FDA does not review them for safety, effectiveness, or quality before they are marketed. That is a statement about regulatory pathway, not an accusation about any particular pharmacy, and it is why the distinction matters more than marketing language does. A compounded preparation is not a generic and not an equivalent of any FDA-approved brand product. Published clinical trials such as SURMOUNT-1 studied the branded product at studied doses; those findings should not be assumed to transfer. What compounded means unpacks the legal framework, and red flags when buying online covers how to tell a legitimate pharmacy from a grey-market seller.
Why side effects are mostly digestive, and mostly early
Because the receptors tirzepatide acts on sit in the gut and the brainstem, the predictable effects are digestive: nausea, reflux, constipation, diarrhoea, and a feeling of fullness that arrives sooner than expected. According to FDA prescribing information for tirzepatide products, gastrointestinal reactions are the most commonly reported adverse events, and they are dose-related for many people. The practical implication is that they tend to cluster around a dose change rather than persist indefinitely. Serious risks are listed separately in the label, including pancreatitis, gallbladder disease, and a boxed warning for thyroid C-cell tumours in rodents. Those are not common, but they are the reason the medication is prescription-only. Report severe or persistent abdominal pain, vomiting that stops you keeping fluids down, or vision changes to your clinician promptly rather than waiting for a scheduled check-in.
No card needed to see it. No insurance accepted or required.
Frequently asked questions
Will it grow back?
In typical telogen effluvium, yes – over several months as weight and nutrition stabilize.
Should I stop Zepbound to save my hair?
Talk to your clinician before changing anything. Pace adjustments usually address the trigger without abandoning progress.
Does this happen with semaglutide too?
Yes – it is reported across weight-loss methods because the trigger is the loss itself, not one molecule.
Is compounded tirzepatide the same as Zepbound?
No. Zepbound is an FDA-approved product; a compounded preparation is made by a licensed pharmacy for an individual patient and is not FDA-approved. FDA does not review compounded preparations for safety, effectiveness, or quality before marketing, and a compounded preparation is not a generic or an equivalent.
What is the starting dose of compounded tirzepatide?
Your prescribing clinician sets the starting dose and the titration schedule, and the dispensing pharmacy supplies instructions for your specific concentration. There is no single published starting dose for compounded preparations, and units and milligrams are not interchangeable.
How long can compounded tirzepatide be out of the fridge?
Follow the storage instructions supplied with your preparation, because the permitted excursion window depends on the exact formulation. If a package arrives warm, leaking, cloudy, or damaged, contact the dispensing pharmacy rather than using it.
Shedding on a GLP-1? Get real guidance
A licensed clinician reviews your history and decides what is appropriate. Rx only, refunded in full if you are not prescribed.
Rx only. A licensed clinician decides whether treatment is appropriate and may determine that no treatment, or a different treatment, is right for you. Compounded medications are not FDA-approved and are not reviewed by FDA for safety, effectiveness, or quality before marketing. Individual results vary.
Sources
Clinical trials listed below evaluated FDA-approved products at the doses studied. They are cited as published science, not as evidence about any compounded preparation, which is not FDA-approved and has not been evaluated by FDA for safety, effectiveness, or quality.
- FDAFDA prescribing information: Zepbound (adverse reactions)
- Peer-reviewedMalkud S. Telogen effluvium: a review. J Clin Diagn Res 2015;9(9):WE01-3
- FDA databaseDrugs@FDA: search approved labeling for tirzepatide
- Peer-reviewedSURMOUNT-1: Tirzepatide Once Weekly for the Treatment of Obesity (NEJM 2022)
Spotted something inaccurate? Report an error – corrections are logged per our editorial standards.
More on Brand-Name Pens
Same medication, different question.